In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company’s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen’s unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen’s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland’s BioHealth Capital Region has supported the company’s innovation and growth.
Listen now on your favorite podcast platform:
Apple: https://apple.co/3IdIAPi
Spotify: https://bit.ly/4eKJIGo
iHeart: https://ihr.fm/4krFxAy
YouTube: https://bit.ly/4lnRUPq
Amazon Music: https://amzn.to/4nG3Tt6
TuneIn: https://bit.ly/4lqEaTG
Editing and post-production work for this episode was provided by The Podcast Consultant.